Speaker: Stephan M. Koza, Ph.D.
Stephan has worked at Waters Corporation for fourteen years and has a primary focus on the
development and use of LC, LC-MS, and sample preparation chemistries for the analysis of
biomolecules. Prior to joining Waters, he had over twenty years of experience with
biopharmaceutical characterization and analytical method development with Genetics
Institute, Wyeth, and Pfizer. Stephan received his graduate degree in Analytical Chemistry at
the University of New Hampshire.
Registration: https://us06web.zoom.us/webinar/register/WN_iItv2nM9TpaEoUaJuPgYng
Event Overview: In the race to launch GLP 1 generics and novel agonists, complex impurity analyses directly impact your speed to market. Conventional columns often obscure peaks of critical impurities, leading to costly rework and increased regulatory scrutiny. Join us and learn about new analytical tools designed to streamline your process and deliver reproducible, high-resolution separations of GLP 1 receptor agonists (GLP-1 RAs) and insulin-related impurities without relying on suppressive mobile phase additives. Learn how improved resolution can accelerate method development, increase confidence in your results, and support faster time to market for your GLP-1 RA and insulin products. I
In this webinar you will learn:
